RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Trial details
- Registry ID
- NCT06328777
- Drugs studied
- CABA-201
TrialRedline tracks 2 clinical trials sponsored by Cabaletta Bio: 2 Phase 2 / 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic SclerosisNCT06328777 | CABA-201 | Recruiting | 2029-07Estimated |
| RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory MyopathyNCT06154252 | CABA-201 following preconditioning with fludarabine and cyclophosphamide | Recruiting | 2028-07Estimated |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate incidence of adverse events. After: Measure: Phase 1/2: To evaluate incidence of adverse events Measure: Phase 2b Sub-study: To evaluate the efficacy of CABA-201 on % predicted forced vital capacity (FVC) in SSc-ILD subjects.
Before: 12 participants (planned). After: 37 participants (planned).
Before: PHASE1, PHASE2. After: PHASE2, PHASE3.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate adverse events reported by subjects. After: Measure: Phase 1/2: Incidence and severity of adverse events (AEs) Measure: Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids Measure: Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids.
Before: 24 participants (planned). After: 74 participants (planned).
Before: PHASE1, PHASE2. After: PHASE2, PHASE3.